Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Amgen Making Fresh Start in the Japanese Market through Joint Venture with Astellas; Pathway to Independent Operation Remains Nebulous
October 18, 2013
- Eisai Inc to Increase Belviq Sales Reps to 400 in US
October 17, 2013
- Toho Pharmaceutical’s Logistics Base TBC Sapporo Starts Operations: Toho Holdings
October 17, 2013
- NBI, Eli Lilly Submit NDA for SGLT-2 Inhibitor
October 17, 2013
- Gilead to Fully Enter Japan, File for Approval for Hepatitis C Treatment Sofosbuvir in 2014: President
October 16, 2013
- Otsuka Completes Acquisition of US Biotech Startup Astex
October 16, 2013
- Janssen, AZ to Copromote Prostate Cancer Treatment Abiraterone in Japan
October 16, 2013
- Once-Weekly DPP-4 Inhibitors of MSD, Takeda to Bring New Dimension to Packed Market
October 15, 2013
- Santen Launches Preservative-Free Tapros Mini Ophthalmic Solution
October 15, 2013
- Kowa Files for Approval of Glaucoma Treatment K-115
October 15, 2013
- Otsuka, Lundbeck Initiate Multinational PIII Program of Novel AD Treatment Lu AE58054
October 15, 2013
- Gilead to Enter Japan Full Force with Hepatitis C Treatment
October 11, 2013
- PAREXEL CEO Says Japan Will Remain as Important Market for CROs, Hopes Outsourcing Increases in Japan
October 11, 2013
- Ono to Set Up Local Subsidiary in South Korea, Eyeing Commercialization of Own Brands
October 11, 2013
- 36 Drug Makers Paid Approximately 400 Billion Yen to Doctors, Medical Institutions in FY2012; Mainly for R&D, But Also for Information
October 11, 2013
- 36 Drug Makers Spent 120 Billion Yen on Information Provision; Foreign-affiliated Companies Top Spending List
October 11, 2013
- DSP to Set Up New Anticancer Drug Sales Company in US, Eyes Launch of BBI608
October 10, 2013
- Kaketsuken Submits 1st Japan-Made Hemophilia Inhibitor Treatment for Approval
October 9, 2013
- Takeda’s Norovirus Vaccine Misses Primary Endpoint in PI/II, but Reduces Vomiting, Diarrhea
October 9, 2013
- Chugai Files NDA for ALK Inhibitor Alectinib in Japan for NSCLC
October 9, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…